African Medicines Agency progress: What You Need to Know
The African Medicines Agency is making strides in improving drug regulation and access, crucial for combating diseases like malaria and enhancing healthcare in Africa.
Quick Answer
The African Medicines Agency is making strides in improving drug regulation and access, crucial for combating diseases like malaria and enhancing healthcare in Africa.
Key Questions
- What is the African Medicines Agency and when did its treaty enter force?
- How does the AMRH programme support AMA's operationalization?
- What is the Continental Listing of Medicinal Products pilot?
- How many countries have ratified the AMA Treaty?
The African Medicines Agency (AMA) has won ratification from 31 African Union member states as of January 2026 and is moving from treaty to real operations. Through the Continental Listing of Medicinal Products pilot and partnerships with Regional Economic Communities, AMA aims to cut duplicate drug reviews and speed patient access to vital medicines across Africa.
Contents9 sections
Key Takeaways
- Ratification milestone: 31 AU member states have ratified the AMA Treaty as of January 2026, up from the 15 needed for the treaty to take effect on 5 November 2021, per the African Medicines Agency's official tracker.
- Continental Listing pilot: Approved in August 2023 at the 9th African Medicines Regulators Conference, the pilot lets an Evaluation of Medicinal Products Technical Committee assess priority drugs for national registration advice.
- Operational backbone: The African Medicines Regulatory Harmonization (AMRH) programme, launched in 2009 by AUDA-NEPAD with WHO backing, runs joint reviews through Regional Economic Communities.
- National capacity: South Africa's Health Products Regulatory Authority (SAHPRA) and Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) bring deep technical skill that strengthens joint reviews.
- Strategic watch: Drug makers should track AMA's pilot outcomes and align file strategies with common standards to gain faster market access.
How Did AMA Evolve From Treaty to Agency?
The African Medicines Agency is a continental effort to unify drug oversight. The African Union adopted the AMA Treaty in February 2019 at the 32nd Session of the Assembly of Heads of State and Government. The treaty took effect on 5 November 2021 after the African Union Commission received the 15th ratification. By January 2026, 31 member states had ratified the treaty, signaling broad political support for common drug approval standards.
AMA's headquarters opened in Kigali, Rwanda. The agency now shifts from legal setup to daily work. Peer-reviewed work in Frontiers in Medicine (2026) traces this shift from the African Medicines Regulatory Harmonization (AMRH) programme, launched in 2009, through treaty adoption to today's pilot programmes.
Fragmented national drug approval systems have long delayed patient access. Countries used separate approval rules, duplicate file reviews, and uneven safety standards. This patchwork deterred drug investment and slowed market entry for both new and generic medicines. A unified framework promises to cut these barriers.
What Frameworks Drive Drug Rule Harmonization?
AMA rests on two main pillars. The AU Model Law on Medical Products Regulation offers member states a legal template they can adopt or adapt within national laws. This respects national independence while creating enough alignment for cross-border drug rule cooperation.
The AMRH programme serves as the operational engine. AUDA-NEPAD launched AMRH in 2009 with WHO backing, well before AMA's formal birth. AMRH coordinates joint drug reviews through Regional Economic Communities. Multiple national agencies within a community pool skill, share resources, and reach common decisions. Compared with old parallel national reviews, this model trims duplication and shortens timelines.
Regional Economic Communities put the vision into practice. They run joint reviews of drug application files while keeping member states responsible for final approvals. This structure helps smaller or less-resourced national bodies tap into shared skill. It also sets common review methods across borders.
Regional Economic Communities and Joint Reviews
| Milestone | Date | Significance |
|---|---|---|
| AMRH programme launched | 2009 | Laid groundwork for continental alignment |
| AMA Treaty adopted | February 2019 | Approved by 32nd AU Assembly of Heads of State |
| Treaty took effect | 5 November 2021 | 15 ratifications deposited at AU Commission |
| Continental Listing pilot approved | August 2023 | Endorsed at 9th African Medicines Regulators Conference |
| 31 states ratified | January 2026 | Majority of AU member states on board |
The table above shows AMA's growth from idea to pilot operations. Each stage built on past work. The 2009 AMRH launch created the technical committees and regional partnerships that now feed into AMA's daily work.
Joint reviews already run in several Regional Economic Communities. The East African Community, the Economic Community of West African States, and the Southern African Development Community each maintain drug harmonisation efforts. These predate AMA and now align with its continental goals.
National agencies such as South Africa's Health Products Regulatory Authority (SAHPRA) and Nigeria's National Agency for Food and Drug Administration and Control (NAFDAC) supply deep technical skill. Their role lends credibility to joint reviews and helps guide smaller agencies.
What Does the Continental Listing Pilot Involve?
In August 2023, the 9th African Medicines Regulators Conference approved a pilot for the Continental Listing of Medicinal Products. AUDA-NEPAD asked drug makers to test phase 1 of this continental review process. An Evaluation of Medicinal Products Technical Committee (EMP-TC) reviews priority drugs at the continental level. A separate Good Manufacturing Practices Technical Committee (GMP-TC) checks production quality. The African Medicines Quality Forum and the African Vaccines Regulatory Forum support lab work where needed.
Companies submit applications for priority products. The EMP-TC runs scientific reviews and issues advice that national drug agencies can use for registration choices. This pilot marks AMA's first concrete step toward a unified continental review path.
Market Impact: Opening Access for Drug Makers
AMA's frameworks reshape market access across Africa. Under the old model, firms filed separate applications in each country. Each review needed its own file, timeline, and fee. Common standards let firms pursue a single review that multiple countries accept.
This shift matters for both global innovators and local generic makers. Innovators gain faster time-to-market and lower review costs. Generic makers, especially those in Africa, can scale production across borders without facing 54 separate rulebooks. The result should be more competition, lower prices, and wider patient access.
Challenges remain. Not every national agency has equal lab capacity or staff skill. Sustained investment in training, digital tools for electronic file submission, and post-market tracking systems stays vital.
Future Outlook: From Ratification to Operations
AMA's path points toward growing membership and deeper drug review integration. As the agency shows it can align approvals without weakening safety standards, more African Union member states are likely to ratify. Each new ratification widens the market covered by joint reviews and continental listings.
Close ties with national agencies will deepen. SAHPRA, NAFDAC, and other experienced bodies will likely guide newer ones. A tiered system is forming: national agencies keep main responsibility for their markets, while AMA coordinates cross-border alignment.
Drug firms should watch AMA's pilot results and framework updates. Firms that align file preparation with common drug rules early may gain first-mover advantage as continental paths mature.
Frequently Asked Questions
What is the African Medicines Agency and when did its treaty enter force?
The African Medicines Agency (AMA) is a continental regulatory body created by the African Union to harmonise pharmaceutical standards across Africa. The AU adopted the AMA Treaty in February 2019. It entered into force on 5 November 2021.
How does the AMRH programme support AMA's operationalization?
The African Medicines Regulatory Harmonization (AMRH) programme, launched in 2009 by AUDA-NEPAD, serves as the operational backbone for AMA. It facilitates joint regulatory assessments through Regional Economic Communities and coordinates technical committees that evaluate medicines for continental listing.
What is the Continental Listing of Medicinal Products pilot?
The Continental Listing pilot is a phase 1 procedure approved in August 2023 at the 9th African Medicines Regulators Conference. An Evaluation of Medicinal Products Technical Committee assesses priority medicines at the continental level and provides scientific recommendations to national regulatory authorities for product registration.
How many countries have ratified the AMA Treaty?
As of January 2026, 31 African Union member states have ratified the AMA Treaty. The treaty entered into force after the 15th ratification in November 2021.
Primary Sources
- African Medicines Agency. "Ratifications." AU-AMA, Jan 2026. https://au-ama.africa/ratifications/
- Ismail AJ, Darko DM, Walker S, Salek S. "The African Medicines Agency: historical perspective of its origins, evolution, institutional structure and future prospects." Front Med (Lausanne). 2026 Feb 4;13:1763261. https://pmc.ncbi.nlm.nih.gov/articles/PMC12913070/
- World Health Organization. "Harmonization of technical requirements for medicines regulation." WHO Regulation and Prequalification. https://www.who.int/teams/regulation-prequalification/regulation-and-safety/regulatory-convergence-networks/harmonization
- AUDA-NEPAD. "Call for Industry Applications: Pilot of the Continental Listing of Medicinal Products." Nov 2023. https://www.nepad.org/publication/call-industry-applications-pilot-of-continental-listing-of-medicinal-products
- African Union. "High-level Working Breakfast on Operationalizing the African Medicines Agency (AMA)." 16 Feb 2024. https://au.int/en/newsevents/20240216/high-level-working-breakfast-operationalizing-african-medicines-agency-ama
This article follows our editorial standards. Report a correction via editorial contact.
